New Breast Cancer Treatment Launches In Sweden, Denmark And Finland
 

Halaven(TM) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease is launched today in Sweden, Denmark and Finland after approval by the European Drug Agency (EU) for the whole EU area by March 24, 2011...

More...